menu
    • menu
    [{"orgOrder":0,"company":"Eisai","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Loxapine Succinate","moa":"5-HT2C receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eisai","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eisai \/ CNX Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ CNX Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Loxapine Succinate

    Menu

    Loxapine Succinate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eisai

                            Japan arrow
                            AGGSpend
                            Not Confirmed

                            Eisai

                            Japan arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loxapine Succinate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : CNX Therapeutics

                            Deal Size : $61.3 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Eisai Divests Rights to Loxapac and Parkinane LP to CNX Therapeutics

                            Details : Through the divestment, the company has acquired the rights and will concentrate on commercializing Loxacin (loxapine succinate) for treating psychotic disorders and personality disorders.

                            Product Name : Loxapac

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 04, 2024

                            Lead Product(s) : Loxapine Succinate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : CNX Therapeutics

                            Deal Size : $61.3 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth